Medicare Enrolled
Dr. Mark Gudesblatt, M.D.
Neurology · Islip, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Gudesblatt from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gudesblatt?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gudesblatt
Dr. Mark Gudesblatt is a neurology specialist in Islip, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Gudesblatt performed 69,952 Medicare services across 5,201 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gudesblatt received a total of $277,514 from 67 pharmaceutical and/or device companies across 785 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gudesblatt is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in NY
$277,514 industry payments
Medicare Practice Summary
Medicare Utilization ↗69,952
Medicare services
Top 1% in NY for neurology
5,201
Unique beneficiaries
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,498 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, natalizumab, 1 mg | 52,022 | $19 | $30 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
3,816 | $19 | $93 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
1,691 | $60 | $370 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
1,144 | $0 | $41 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
1,061 | $4 | $31 |
| Anti-nausea injection (ondansetron/Zofran) | 932 | $0 | $10 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
848 | $15 | $80 |
| Psychological test administration, each additional 30 minutes A technician administers psychological or neuropsychological testing. This code covers each additional 30-minute increment of administration time. |
739 | $33 | $234 |
| Psychological test administration, first 30 minutes A technician administers psychological or neuropsychological testing for the first 30 minutes. |
714 | $32 | $235 |
| Neuropsychological test evaluation, first hour A professional assessment of cognitive and behavioral functioning using standardized tests. This service covers the initial hour of the evaluation process. |
704 | $112 | $588 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
699 | $145 | $479 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
620 | $0 | $14 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
598 | $19 | $49 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 508 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
417 | $102 | $396 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
406 | $12 | $50 |
| Physician review of gait analysis test A physician reviews the results of a gait analysis test. This procedure involves the professional interpretation of data collected during the assessment of a patient's walking pattern. |
392 | $99 | $368 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
382 | $1 | $4 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
371 | $1 | $21 |
| Refilling and maintenance of implantable drug delivery pump This procedure involves refilling and maintaining an implanted pump or reservoir used for delivering medication. It ensures the device functions correctly to provide continuous drug delivery. |
263 | $115 | $251 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
238 | $8 | $19 |
| 3D gait analysis with foot pressure measurement A test that uses 3D video and computer technology to evaluate walking patterns. It measures the pressure distribution across the feet during movement. |
214 | $94 | $253 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
136 | $13 | $111 |
| New patient office visit, complex (60-74 min) | 136 | $190 | $757 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
136 | $159 | $1,268 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
131 | $36 | $335 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
114 | $1 | $10 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
109 | $30 | $315 |
| Baclofen injection, 10 mg A 10 mg dose of the muscle relaxant baclofen is injected into the body. |
99 | $142 | $275 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
44 | $25 | $119 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
42 | $110 | $385 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
31 | $100 | $527 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
31 | $0 | $0 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $157 | $997 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
26 | $75 | $310 |
| Eye deviation and range of motion exam An examination to measure eye deviation and assess the range of motion of the eyes. |
21 | $59 | $115 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
17 | $121 | $700 |
| Home health plan of care certification Certification by a physician or allowed practitioner for Medicare-covered home health services under a home health plan of care. This includes contacting the home health agency and reviewing reports of patient status required by physicians. |
16 | $33 | $100 |
| Rituximab injection, 10 mg Administration of a 10 mg dose of rituximab medication via injection. |
16 | $0 | $0 |
| Spinal drug pump reprogramming and refill A physician electronically adjusts the settings of a spinal drug infusion pump and refills its medication reservoir. |
15 | $90 | $300 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
14 | $73 | $519 |
| EEG, extended monitoring A test that records electrical activity in the brain while the patient is both awake and asleep. |
13 | $50 | $285 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.1% high complexity
81.4% medium
7.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$277,514
Total received (2018-2024)
Avg $39,645/year across 7 years
Top 3% in NY for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
67
Companies
785
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$241,984 (87.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$22,779 (8.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,751 (4.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$984
2023
$14,145
2022
$27,153
2021
$33,238
2020
$48,854
2019
$81,508
2018
$71,632
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$247
Biogen, Inc.
$131
JAZZ PHARMACEUTICALS INC.
$127
TG Therapeutics, Inc.
$114
ACADIA Pharmaceuticals Inc
$105
Takeda Pharmaceuticals U.S.A., Inc.
$93
CATALYST PHARMACEUTICALS, INC.
$43
EMD Serono, Inc.
$38
Novartis Pharmaceuticals Corporation
$34
PFIZER INC.
$26
Lilly USA, LLC
$25
Top 3 companies account for 51.4% of 2024 payments
All-time payments by company (2018-2024) ›
Biogen, Inc.
$131,294
GENZYME CORPORATION
$25,020
Celgene Corporation
$17,504
Alexion Pharmaceuticals, Inc.
$17,174
EMD Serono, Inc.
$14,811
Genentech USA, Inc.
$14,345
Acorda Therapeutics, Inc
$10,256
Novartis Pharmaceuticals Corporation
$9,199
F. Hoffmann-La Roche AG
$6,000
E.R. Squibb & Sons, L.L.C.
$5,691
Eisai Inc.
$4,254
Teva Pharmaceuticals USA, Inc.
$3,241
JAZZ PHARMACEUTICALS INC.
$3,084
Genentech, Inc.
$2,509
AbbVie Inc.
$2,293
Horizon Therapeutics plc
$2,135
CATALYST PHARMACEUTICALS, INC.
$1,573
Janssen Pharmaceuticals, Inc
$1,500
AbbVie, Inc.
$1,275
Banner Life Sciences, LLC
$800
Amgen Inc.
$392
Avanir Pharmaceuticals, Inc.
$301
Braemar Manufacturing, LLC
$232
Boston Scientific Corporation
$181
Medtronic, Inc.
$169
Mitsubishi Tanabe Pharma America, Inc.
$135
ACADIA Pharmaceuticals Inc
$130
TG THERAPEUTICS, INC.
$129
ABBVIE INC.
$121
Piramal Critical Care
$119
TG Therapeutics, Inc.
$114
SANOFI-AVENTIS U.S. LLC
$107
Abbott Laboratories
$94
Takeda Pharmaceuticals U.S.A., Inc.
$93
PFIZER INC.
$90
Mallinckrodt LLC
$78
Allergan, Inc.
$76
Allergan Inc.
$70
Medtronic USA, Inc.
$66
Neurocrine Biosciences, Inc.
$59
Adamas Pharmaceuticals, Inc.
$56
Arbor Pharmaceuticals, Inc.
$51
CSL Behring
$48
Amneal Pharmaceuticals LLC
$47
Lilly USA, LLC
$42
GRT US Holding, Inc.
$41
Catalyst Pharmaceuticals, Inc.
$40
UCB, Inc.
$38
Avion Pharmaceuticals
$35
Scilex Pharmaceuticals Inc.
$35
Merz Pharmaceuticals, LLC
$34
Collegium Pharmaceutical, Inc.
$33
BOSTON SCIENTIFIC CORPORATION
$33
W. L. Gore & Associates, Inc.
$31
Bard Peripheral Vascular, Inc.
$27
Alnylam Pharmaceuticals Inc.
$24
Merz North America, Inc.
$23
PIRAMAL CRITICAL CARE
$21
Sunovion Pharmaceuticals Inc.
$18
Mallinckrodt Hospital Products Inc.
$18
Octapharma USA, Inc.
$17
Greenwich Biosciences, Inc.
$17
Saol Therapeutics Inc.
$16
Lundbeck LLC
$15
BANNER LIFE SCIENCES, LLC
$14
GE HEALTHCARE
$13
Supernus Pharmaceuticals, Inc.
$13
Top 3 companies account for 62.6% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ACTIVA · ADUHELM · AIMOVIG · AMPYRA · AMYVID · APTIOM · AUBAGIO · AUSTEDO · AVONEX · Aduhelm · Aimovig · BAFIERTAM · BOTOX · BRIUMVI · Bafiertam · Briviact · CARDIOFORM Septal Occluder · COPAXONE · Cardiac Monitoring Suite · DAYBUE · DISEASE STATE · Dhivy · Epidiolex · FIRDAPSE · FYCOMPA · GABLOFEN · GABLOFEN 1 mL in 1 SYRINGE · GENERAL DBS · GILENYA · GLASS · GOCOVRI · HYQVIA · Hizentra · Horizant · INBRIJA · INFINITY · INGREZZA · Infinity DBS Pulse Generators · KESIMPTA · KISUNLA · LEMTRADA · LINZESS · Leqembi · Lioresal Intrathecal (baclofen injection) · MAVENCLAD · MAYZENT · MS DISEASE STATE · Mavenclad · NAMZARIC · NO PRODUCT DISCUSSED · NUEDEXTA · NUPLAZID · NURTEC ODT · Nuedexta · OCREVUS · ONPATTRO · Ocrevus · Ongentys · Ozanimod · PANZYGA · PERCEPT PC BRAINSENSE · PLEGRIDY · POWERPORT · QELBREE · QULIPTA · Qutenza · RYTARY · Radicava · Rebif · SOLIRIS · SUVECALTAMIDE · SYNCHROMED · SYNCHROMEDII · Soliris · TECFIDERA · TYSABRI · Tamiflu · Tysabri · UBRELVY · UPLIZNA · VERCISE · VUMERITY · VYEPTI · Vumerity · WATCHMAN FLX · XEOMIN · XTAMPZA · XYWAV · Xeomin · ZEPOSIA · ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (87%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for neurology in NY.
Geographic Context
Neurologists within 10 mi
186
Per 100K population
12.2
County median income
$128,329
Nearest hospital
NS/LIJ HS SOUTHSIDE HOSPITAL
2.0 mi
2.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Gudesblatt is a mixed practice specialist, with above-average Medicare volume (top 1% in NY), with speaking/promotional industry engagement in the top 3% of NY peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Gudesblatt experienced with injection, natalizumab, 1 mg?
Based on Medicare claims data, Dr. Gudesblatt performed 52,022 injection, natalizumab, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gudesblatt receive payments from pharmaceutical companies?
Yes. Dr. Gudesblatt received a total of $277,514 from 67 companies across 785 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gudesblatt's costs compare to other neurologists in Islip?
Dr. Gudesblatt's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gudesblatt) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Islip
Browse neurologists in Islip ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in NY
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in NY
Which NY neurologists receive the most from drug and device companies.
By company
Biogen, Inc. Payments to Doctors
See all physicians who received payments from Biogen, Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology